Cannabigerol has not been studied in humans. But there is interest in its use for various neurologic disorders, abnormal levels of cholesterol or blood fats, and to stimulate appetite.
How does it work ?
Uses & Effectiveness ?
Insufficient Evidence for
- Abnormal levels of cholesterol or blood fats (dyslipidemia).
- An inherited brain disorder that affects movements, emotions, and thinking (Huntington disease).
- Involuntary weight loss in people who are very ill (cachexia or wasting syndrome).
- Long-term swelling (inflammation) in the digestive tract (inflammatory bowel disease or IBD).
- Other conditions.
Special Precautions and Warnings
We currently have no information for CANNABIGEROL (CBG) overview.
Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306-16. View abstract.
Borrelli F, Pagano E, Romano et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014;35(12):2787-97. View abstract.
Brierley DI, Harman JR, Giallourou N, et al. Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. J Cachexia Sarcopenia Muscle. 2019;10(4):844-859. View abstract.
Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. Behav Pharmacol. 2017;28(4):280-284. View abstract.
Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology (Berl). 2016;233(19-20):3603-13. View abstract.
D'Aniello E, Fellous T, Iannotti FA, et al. Identification and characterization of phytocannabinoids as novel dual PPARa/? agonists by a computational and in vitro experimental approach. Biochim Biophys Acta Gen Subj. 2019;1863(3):586-597. View abstract.
Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73. View abstract.
Gugliandolo A, Pollastro F, Grassi G, Bramanti P, Mazzon E. In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid. Int J Mol Sci. 2018;19(7). pii: E1992. View abstract.
Hidvégi E, Somogyi GP. Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption. Pharmazie. 2010;65(6):408-11. View abstract.
Mammana S, Cavalli E, Gugliandolo A, et al. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol. Medicina (Kaunas). 2019;55(11):747. View abstract.
Navarro G, Varani K, Reyes-Resina I, et al. Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Front Pharmacol. 2018;9:632. View abstract.
Pagano E, Montanaro V, Di Girolamo A, et al. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol. Nat Prod Commun. 2015;10(6):1009-12. View abstract.
Rock EM, Goodwin JM, Limebeer CL, et al. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl). 2011;215(3):505-12. View abstract.
Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015;12(1):185-99. View abstract.